S5 - E9.5 - In-Office Screening Post-Rezdiffra: The Importance Of Predictive Biomarkers
Send us a text This conversation focuses on how the need for biomarkers will evolve in an era of in-office screening and MASH drugs and ends with answers to Roger Green's closing question. Hannes Hagstrom starts this conversation by noting that one challenge as MASH drugs become available involves knowing when to discontinue or add to therapy since, as he points out, Rezdiffra will not be efficacious for all patients. This leads Jörn Schattenberg to the need for predictive biomarkers t...
7 Huhti 202414min
S5 - E9.4 - In-office MASLD Screening and the Clinical Care Pathway
Send us a text This conversation explores the implications of increased access to economically viable in-office screening, particularly when primary care practices begin to use the new scanning devices. Roger Green begins this conversation by recalling a concern Naim Alkhouri expressed during S4 E50.3, that primary care reliance on FIB-4 can flood the pathways with many “wrong” patients, which might lead to confusion within the channels. Hannes Hagstrom describes a role for primary care at t...
7 Huhti 202411min
S5 - E9.3 - How Will Increased Access To In-Office Scanning Improve MASLD Therapy:
Send us a text This conversation centers around the different kinds of impact that in-office scanning can have on MASLD therapy, both in terms of improved prognostics and better overall outcomes. Roger Green starts by suggesting that the recent commercialization of a second VCTE in the U.S. (specifically, Hepatoscope from e-Scopics), coupled with increased promotion of the scanning device Velacur from Sonic Incytes, will increase education and promotion dramatically and lead to signifi...
6 Huhti 202411min
S5 - E9.2 - VCTE Studies Demonstrate That Multiple Nutrition Interventions Can Support MASLD Patients
Send us a text This conversation explores why different nutrition interventions might help MASLD patients improve their overall liver health and what lessons treaters and researchers can learn from this. It starts with Louise Campbell discussing a recent publication of a pilot study from Armandi et al. (including Jörn Schattenberg as a co-author) evaluating the ability of short-term dietary gluten reduction to reduce metabolic dysfunction as measured in CAP (controlled attenuation para...
6 Huhti 202410min
S5 - E9.1 - VCTE As A Prognostic And Therapeutic Tool For MASLD
Send us a text This conversation focuses on the role of VCTE in diagnosing, staging and treating MASLD patients, both in terms of prognostic ability of VCTE when compared to biopsy and separately as a therapeutic adjunct. It starts with Hannes Hagstrom and Jörn Schattenberg discussing a study from Vincent Wong and a large group of co-authors, including Hannes,, that compares the abilities or VCTE and biopsy to predict outcomes. After Hannes mentions the studies and makes the key point that V...
6 Huhti 20249min
S5 - E9 - Value of VCTE Or Other In-Office MASLD Monitoring
Send us a text Hannes Hagstrom joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss recent research panelists have conducted. This content-dense conversation focuses initially on the impact of VCTE and other forms of in-office monitoring and branches out from there. 00:00:00 - Surf's Up: Season 5 Episode 9 Opening comments from the panel, including brief quotes taken directly from the episode. 00:02:04 - Introduction and groundbreaker Each panelist shares one piece of good ne...
4 Huhti 202453min
S5 - E8 - Changing Patient Incentives For Participating In MASH Clinical Trials
Send us a text With Louise Campbell and Jörn Schattenberg both on Easter Week vacations, Fatty Liver Alliance Founder Mike Betel joins Roger Green to continue a brief conversation they began in a post from the Fatty Liver Alliance last weekend. This conversation focuses largely on how patient incentives to participate in MASH clinical trials might need to change now that Rezdiffra is approved. 00:00:00 - Introduction Roger explains why Louise and Jörn are not available for this convers...
1 Huhti 202415min
S5 - E7.6 - MASLD Patient Advocates' Recommendations for Others after Rezdiffra Approval
Send us a text So far, this conversation has focused on Rezdiffra approval and its many forms of impact on MASLD patient advocates. This conversation considers their recommendation for others. The conversation starts with Roger Green's final question. He asks each panelist to identify a stakeholder group that can take a valuable lesson from this episode and what that lesson should be. Wayne Eskridge goes first. Wayne focuses on the need for Madrigal and the various professional ...
24 Maalis 20249min
